# Drug-Resistant Infections in Burn Patients: A One-Year Analysis of Microbiological Trends and Predictive Risk Factors in a Romanian Tertiary Care Centre

**Authors:** Oana Izmendi, Baditoiu Luminita, Corina Musuroi, Silvana Vulpie, Delia Muntean, Adela Voinescu, Silvia Ioana Musuroi, Zorin Petrisor Crainiceanu, Panche Taskov, Romanita Jumanca, Monica Licker

PMC · DOI: 10.3390/antibiotics15030307 · Antibiotics · 2026-03-18

## TL;DR

This study analyzed infection trends in burn patients in Romania and found high rates of drug-resistant bacteria, identifying risk factors like severity of burns and hospital stay.

## Contribution

The study identifies specific risk factors for acquiring extensively drug-resistant pathogens in burn patients at a Romanian hospital.

## Key findings

- MDROs were isolated in 59.37% of patients, with 26.56% having at least one XDR pathogen.
- Higher ABSBI score, longer hospital stay, and polymicrobial growth were independent predictors of XDR pathogens.
- The cumulative antibiogram provides a foundation for local antimicrobial stewardship.

## Abstract

Background and Objectives: The susceptibility of burn patients to infections with multidrug-resistant organisms (MDROs) is high. The aim of this study is to describe the local patterns of antimicrobial resistance in a Romanian burn unit and to identify risk factors associated with the acquisition of extensively drug-resistant (XDR) pathogens. Materials and Methods: We conducted a one-year, observational, retrospective single-centre cohort study including all burn patients with at least one positive culture admitted to our unit during 2024. In order to identify the pathogens and perform antibiograms, we used routine microbiological diagnostic tests. A multivariable logistic regression model was used to identify XDR risk factors. We also compiled a cumulative antibiogram using the first non-duplicate isolate per patient, following the CLSI M39 guidelines. Results: Among the 180 total admissions, 128 (71.1%) had at least one positive microbiological culture, resulting in 643 bacterial isolates out of 559 samples. The most frequently identified species were A. baumannii, P. aeruginosa, S. aureus, and K. pneumoniae. We isolated MDROs in 59.37% of patients, and 26.56% had at least one XDR pathogen isolated during hospitalisation. We identified three independent predictors for the isolation of XDR pathogens: a higher Abbreviated Burn Severity Index (ABSI) score (aOR 6.12; p = 0.001), hospital length of stay (LOS) (aOR 1.02; p = 0.030), and the number of bacterial species identified per sample, representing polymicrobial growth (aOR 5.91; p = 0.001). Conclusions: Our findings highlight a significant percentage of MDR and XDR pathogens and provide the foundation for antimicrobial stewardship measures, using the local cumulative antibiogram for empirical therapy.

## Linked entities

- **Diseases:** burns (MONDO:0043519)

## Full-text entities

- **Genes:** beta-lactamase [NCBI Gene 13913583]
- **Diseases:** MRSA (MESH:D013203), ABSI (MESH:D045169), LOS (MESH:D007870), infectious disease (MESH:D003141), Burn injuries (MESH:D002056), allergy (MESH:D004342), Gram-negative infections (MESH:D016905), COVID-19 (MESH:D000086382), MDR (MESH:D018088), urinary tract infections (MESH:D014552), Skin and soft tissue (MESH:D017695), Candidozyma auris bloodstream infection (MESH:D018805), staphylococcal (MESH:D011023), inhalation (MESH:D015208), immune dysfunction (MESH:D007154), ESBL (MESH:C579922), burn wound infections (MESH:D014946), critically ill (MESH:D016638), AMR (MESH:D060467), XDR (MESH:D054908), Infection (MESH:D007239), MLSB (MESH:D006509), burn wounds (MESH:D014947), pulmonary, urinary, and systemic infections (MESH:D012141), coagulase-negative staphylococci (MESH:D064726), Drug-Resistant Infections (MESH:D000069279), deaths (MESH:D003643), Fungal infections (MESH:D009181), Diseases (MESH:D004194)
- **Chemicals:** aztreonam (MESH:D001398), tobramycin (MESH:D014031), cefazolin (MESH:D002437), ceftazidime/avibactam (MESH:C000595613), cefpirome (MESH:C038950), lincosamides (MESH:D055231), silver sulfadiazine (MESH:D012837), gentamicin (MESH:D005839), trimethoprim/sulfamethoxazole (MESH:D015662), sulphonamides (MESH:D013449), macrolides (MESH:D018942), cephalosporins (MESH:D002511), ertapenem (MESH:D000077727), streptogramin B (MESH:D025381), ciprofloxacin (MESH:D002939), piperacillin/tazobactam (MESH:D000077725), aminoglycosides (MESH:D000617), imipenem (MESH:D015378), vancomycin (MESH:D014640), fluoroquinolones (MESH:D024841), ceftriaxone (MESH:D002443), CS (MESH:D002586), ampicillin (MESH:D000667), cefoxitin (MESH:D002440), ticarcillin/clavulanic acid (MESH:C043215), cefotaxime (MESH:D002439), Carbapenem (MESH:D015780), cefuroxime (MESH:D002444), TCC (MESH:C009540), beta-lactam (MESH:D047090), oxacillin (MESH:D010068), CAZ (MESH:D002442), cefepime (MESH:D000077723), amoxicillin/clavulanic acid (MESH:D019980), CTX (-), Methicillin (MESH:D008712), meropenem (MESH:D000077731), FEP (MESH:D011138), CPT (MESH:C000708228), amikacin (MESH:D000583), monobactams (MESH:D008997), AMP (MESH:D000249)
- **Species:** Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Providencia stuartii (species) [taxon 588], Escherichia coli (E. coli, species) [taxon 562], Klebsiella pneumoniae (species) [taxon 573], Aspergillus fumigatus (species) [taxon 746128], Enterococcus (genus) [taxon 1350], Acinetobacter baumannii (species) [taxon 470], Proteus (genus) [taxon 210425], Pseudomonas aeruginosa (species) [taxon 287], Stenotrophomonas maltophilia (species) [taxon 40324], Citrobacter freundii (species) [taxon 546], Enterovirus C (no rank) [taxon 138950], Leclercia adecarboxylata (species) [taxon 83655], Morganella morganii (species) [taxon 582], Homo sapiens (human, species) [taxon 9606], Bacillus cereus (species) [taxon 1396], Pantoea agglomerans (species) [taxon 549], Hoylesella timonensis (species) [taxon 386414], Enterobacterales (order) [taxon 91347], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13023949/full.md

## References

70 references — full list in the complete paper: https://tomesphere.com/paper/PMC13023949/full.md

---
Source: https://tomesphere.com/paper/PMC13023949